Current Trends in the Use of Adrenoblockers in Urology: What Has Been Changed

##plugins.themes.bootstrap3.article.main##

Valerii Zaytsev

Abstract

The main indications and practical features of the use of α1-blockers (AB) in urology are analyzes in the article. Studies show that AB usually reduce IPSS by about 30–40% and increase Qmax by about 20–25%. Recently, there have been changes in the AB usage. They are increasingly used for other indications than the treatment of benign prostatic hyperplasia. This is the restoration of urination after urinary retention and in case of urolithiasis to improve the spontaneous passage of stones through the ureters (including women), although these indications are not officially approved. In addition, AB is increasingly being prescribed by physicians of various specialties (such as general practitioners or emergency physicians) rather than just urologists.


The development and implementation of a system of sustained release of tamsulosin has improved its tolerability by reducing the side effects on the cardiovascular system and expanded the possibilities of its use. High-quality generic tamsulosin preparations (such as Tamsin Forte) with a sustained release system can be a worthy alternative to the original drugs.

##plugins.themes.bootstrap3.article.details##

Section
For practicing physicians
Author Biography

Valerii Zaytsev, Bukovinian State Medical University

Valerii I. Zaytsev,

Department of Urology and Neurosurgery

References

Available from: https://uroweb.org/guideline/treatment-of-non-neurogenicmale-luts/#5

Taub D.A. et al. Cur. Prostate Report. 2006.

Available from: https://www.auanet.org/guidelines/guidelines/benignprostatic-hyperplasia-(bph)-guideline/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014)

Barendrecht M.M., et al. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn. 2008;27:226.

Michel M.C., et al. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 1998;1:332.

Roehrborn C.G., et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123.

Karavitakis M., et al. Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis. Eur Urol, 2019.

Fisher E, Subramonian K, Omar M. The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men. Cochrane Database of Systematic Reviews 2014, Issue 6. Art. No.: CD006744. DOI: 10.1002/14651858.CD006744.pub3

Société Internationale d’Urologie (SIU), Lower Urinary Tract Symptoms (LUTS): An International Consultation on Male LUTS., C. Chapple & P. Abrams, Editors. 2013.

Chang D.F., et al. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005;31:664.

Chatziralli I.P., et al. Risk factors for intraoperative floppy iris syndrome: a metaanalysis. Ophthalmology. 2011;118:730.

Gacci M., et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014;11:1554.

Hordijk I.M.J., Steffens M.G., Hak E. et al. Continuation rates of alpha-blockers mono-therapy in adult men, prescribed by urologists or general practitioners: a pharmacy-based study. World J Urol. 2019;37:1659–64.

Kava BR, Verbeek AE, Wruck JM, Gittelman M. Tamsulosin dispensation patterns in the United States: a realworld, longitudinal, population claims database analysis. Transl Androl Urol. 2019 Aug;8(4):329-38. DOI: 10.21037/tau.2019.07.02. PMID: 31555556; PMCID: PMC6732091

Roehrborn CG, Lowe FC, Gittelman M, Wruck JM, Verbeek AE. Management of Male Lower Urinary Tract Symptoms in a Simulated, Over-the-Counter Setting: An Exploratory Study of Tamsulosin. Drugs Aging. 2019 Feb;36(2):179–88. DOI: 10.1007/s40266-018-0621-8. PMID: 30607798

Campschroer T, Zhu X, Vernooij RWM, Lock M. Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database of Systematic Reviews 2018, Issue 4. Art. No.: CD008509. DOI: 10.1002/14651858.CD008509.pub3

Pourmand A, Nadendla R, Mazer-Amirshahi M, O’Connell F. Tamsulosin for urolithiasis: a review of the recent literature and current controversies. Am J Emerg Med. 2016 Nov;34(11):2217–2221. DOI: 10.1016/j.ajem.2016.09.009. Epub 2016 Sep 8. PMID: 27639296

Neill Mischel, Shahani Rohan, Zlotta Alexandre R. Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic Hypertrophy Therapeutics and Clinical Risk Management. 2008;4(1):11–8.

Gregory Y.H. Lip, John E. Hall, Comprehensive Hypertension, 2007, ISBN 9780323039611. Available from: https://doi.org/10.1016/B978-0-323-03961-1.50001-5